Evidence map›Paper›PMID 37816821›Full record

ArticleNature medicine2024

Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.

Jamie E Chaft, Filiz Oezkan, Mark G Kris, Paul A Bunn, Ignacio I Wistuba, David J Kwiatkowski, Dwight H Owen, Yan Tang, Bruce E Johnson, Jay M Lee and 19 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Jamie E Chaft *Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-5838-9982
Filiz Oezkan *The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Mark G KrisMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Paul A BunnUniversity of Colorado School of Medicine, Aurora, CO, USA.
Ignacio I WistubaThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David J KwiatkowskiDana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5668-5219
Dwight H OwenThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Yan TangBrigham and Women's Hospital, Boston, MA, USA.
Bruce E JohnsonDana-Farber Cancer Institute, Boston, MA, USA.
Jay M LeeDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Gerard LozanskiThe Ohio State University Wexner Medical Center, Columbus, OH, USA.
Maciej PietrzakThe Ohio State University Wexner Medical Center, Columbus, OH, USA.
Michal SewerynThe Ohio State University Wexner Medical Center, Columbus, OH, USA.
Woo Yul ByunThe Ohio State University Wexner Medical Center, Columbus, OH, USA.ORCID http://orcid.org/0000-0001-8686-638X
Katja SchulzeGenentech, Inc., South San Francisco, CA, USA.
Alan NicholasGenentech, Inc., South San Francisco, CA, USA.
Ann JohnsonGenentech, Inc., South San Francisco, CA, USA.
Jessica GrindheimGenentech, Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2149-1622
Stephanie HilzGenentech, Inc., South San Francisco, CA, USA.
David S ShamesGenentech, Inc., South San Francisco, CA, USA.
Chris RivardUniversity of Colorado School of Medicine, Aurora, CO, USA.
Eric TolozaMoffitt Cancer Center and Research Institute, Tampa, FL, USA.
Eric B HauraMoffitt Cancer Center and Research Institute, Tampa, FL, USA.
Ciaran J McNameeDana-Farber Cancer Institute, Boston, MA, USA.
G Alexander PattersonWashington University School of Medicine, St. Louis, MO, USA.
Saiama N WaqarWashington University School of Medicine, St. Louis, MO, USA.
Valerie W RuschMemorial Sloan Kettering Cancer Center, New York, NY, USA.
David P CarboneThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. david.carbone@osumc.edu.ORCID http://orcid.org/0000-0003-3002-1921
LCMC study investigators

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002384
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37816821
PMCPMC10803254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.